Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Elias Kouchakji"'
Autor:
Eduard Gorina, Elias Kouchakji, Ulrich Costabel, Mary Beth Scholand, Seth Porter, Kin-Hung Peony Yu, Thomas B. Neff, David J. Lederer, Ganesh Raghu, Carlo Albera, Luca Richeldi, Kevin R. Flaherty, Ming Zhong, Rafael Perez, Jonathan G. Goldin, Neil Ettinger, Evans R. Fernández Pérez
Summary Background Connective tissue growth factor (CTGF) is a secreted glycoprotein that has a central role in the process of fibrosis. This study was designed to assess the safety, tolerability, and efficacy of pamrevlumab (FG-3019), a fully recomb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e64e208e9576cc90248ac3146c3c69f
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85076432720
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85076432720
Publikováno v:
Idiopathic interstitial pneumonias.
Patient-reported outcomes (PROs) are key in assessing health-related QoL with SGRQ as one of the most common tools in IPF. qHRCT is used to diagnose IPF and assess treatment effect and disease progression. Pamrevlumab, a mAb against connective tissue
Autor:
Neil Ettinger, Eduard Gorina, Rafael Perez, Ganesh Raghu, Carlo Albera, Evans R. Fernández Pérez, Kevin R. Flaherty, Ulrich Costabel, Jonathan G. Goldin, Luca Richeldi, David J. Lederer, Kin-Hung Peony Yu, Thomas B. Neff, Mary Beth Scholand, Seth Porter, Ming Zhong, Elias Kouchakji
Publikováno v:
SSRN Electronic Journal.
Background: This Phase 2 study evaluated the safety, tolerability, and efficacy of pamrevlumab (FG-3019), a human monoclonal antibody against connective tissue growth factor, in idiopathic pulmonary fibrosis (IPF). The study was designed to evaluate
Autor:
Marc R. Matrana, Timothy V. Larson, Michael J. Pishvaian, Jordan M. Winter, John A. Glaspy, Flavio G. Rocha, Ming Zhong, Elias Kouchakji, Vincent J. Picozzi, Mairead Carney, Tom Neff, Ewa Carrier, Kabir Mody, Seth Porter
Publikováno v:
SSRN Electronic Journal.
Background: Pancreatic ductal adenocarcinomas (PDAC) exhibit a high degree of desmoplasia with extensive connective tissue growth factor (CTGF) expression and extracellular matrix production. Tumor response and potential for resection in locally adva
Autor:
Elias Kouchakji, Seth Porter, Eduard Gorina, J. De Backer, Benjamin Mignot, Johan Clukers, J. Roseman, W. De Backer, Maarten Lanclus, K. E. Lipson, C. Van Holsbeke
Publikováno v:
Respiratory Research
Respiratory Research, Vol 19, Iss 1, Pp 1-9 (2018)
Respiratory research
Respiratory Research, Vol 19, Iss 1, Pp 1-9 (2018)
Respiratory research
Background Idiopathic pulmonary fibrosis (IPF) is chronic fibrosing pneumonia with an unpredictable natural disease history. Functional respiratory imaging (FRI) has potential to better characterize this disease. The aim of this study was to identify
Autor:
Mairead Carney, Mark D. Sternlicht, Dongxia Li, Todd W. Seeley, Elias Kouchakji, Kenneth E. Lipson, Viet-Tam L. Nguyen, Ewa Carrier, Vincent J. Picozzi, Duo Zhou
Publikováno v:
Journal of Clinical Oncology. 38:752-752
752 Background: Pancreatic ductal adenocarcinomas (PDAC) often exhibit desmoplasia, elevated CTGF (connective tissue growth factor) expression and inflammation. The influence of inflammation on patient outcomes was examined in a dose-ranging trial of
Autor:
Jordan Winter, Ewa Carrier, Marc R. Matrana, Mairead Carney, Kabir Mody, Seth Porter, John A. Glaspy, Adnan Alseidi, Flavio G. Rocha, Vincent J. Picozzi, Michael J. Pishvaian, Timothy V. Larson, Elias Kouchakji
Publikováno v:
ESMO Open
Purpose Pancreatic ductal adenocarcinomas exhibit a high degree of desmoplasia due to extensive extracellular matrix deposition. Encasement of mesenteric vessels by stroma in locally advanced pancreatic cancer (LAPC) prevents surgical resection. This
Autor:
Elias Kouchakji, John E. Fitzgerald, Peter Lacamera, Jeffrey J. Swigris, Mark J. Hamblin, Joao deAndrade, Ming Zhong, Peter Bercz, Rafael Perez, Peony Yu, Eduard Gorina, Thomas B. Neff, Tro Sekayan
Publikováno v:
Idiopathic interstitial pneumonias.
Dyspnea is a meaningful outcome to patients with IPF. Pamrevlumab, a mAb against connective tissue growth factor, has shown favorable safety, efficacy and QoL (SGRQ) results in PRAISE, a Phase 2, placebo-controlled trial. The UCSD-SOBQ is a respirato
Autor:
Wim Vos, Elias Kouchakji, Seth Porter, Maarten Lanclus, Jan De Backer, Benjamin Mignot, Eduard Gorina, Wilfried De Backer, Charles Mussche, Johan Clukers, Cedric Van Holsbeke, Jonathan G. Goldin
Publikováno v:
Clinical Problems.
Aims and objectives To identify baseline FRI parameters that predict changes in FVC and fibrosis after 48w of treatment with FG3019 Methods: In this open label study, 66 IPF patients (67.9±7.0 years) completed 48 weeks of treatment with an anti-CTGF
Autor:
Carlo Albera, Eduard Gorina, Bhanu Singh, Ganesh Raghu, Kevin R. Flaherty, Rafael Perez, Evans R. Fernández Pérez, Neil Ettinger, David J. Lederer, Elias Kouchakji, Peter Bercz, Ulrich Costabel, Jonathan G. Goldin, Luca Richeldi, Seth Porter
Publikováno v:
Diffuse Parenchymal Lung Disease.
Drugs currently approved for treatment of idiopathic pulmonary fibrosis (IPF) (pirfenidone or nintedanib) slow the decline of FVC (forced vital capacity) over time. Nonetheless, there is still a medical need for effective and better tolerated therapi